PRIGNANO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.308
EU - Europa 5.066
AS - Asia 1.348
AF - Africa 97
OC - Oceania 65
SA - Sud America 9
Totale 13.893
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.282
RU - Federazione Russa 1.854
PL - Polonia 1.100
IT - Italia 649
IE - Irlanda 603
SG - Singapore 511
SE - Svezia 438
HK - Hong Kong 380
CN - Cina 235
DE - Germania 109
FI - Finlandia 99
CI - Costa d'Avorio 94
JO - Giordania 72
GB - Regno Unito 68
IN - India 67
AU - Australia 65
UA - Ucraina 52
CH - Svizzera 43
TR - Turchia 29
CA - Canada 26
ID - Indonesia 25
VN - Vietnam 18
BE - Belgio 12
FR - Francia 12
NL - Olanda 11
AR - Argentina 6
ES - Italia 5
KR - Corea 5
IR - Iran 4
AT - Austria 2
BR - Brasile 2
EG - Egitto 2
LT - Lituania 2
SM - San Marino 2
CZ - Repubblica Ceca 1
GR - Grecia 1
IL - Israele 1
IQ - Iraq 1
MU - Mauritius 1
NO - Norvegia 1
PE - Perù 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 13.893
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.396
Warsaw 1.098
Dublin 600
Fairfield 585
Chandler 553
Singapore 437
Woodbridge 276
Lawrence 274
Altamura 272
Ashburn 272
Hong Kong 238
Wilmington 219
Seattle 217
Cambridge 213
Houston 203
Princeton 174
Buffalo 170
Medford 148
Moscow 124
Ann Arbor 111
Abidjan 94
San Diego 92
Jacksonville 84
Beijing 61
Melbourne 60
Shanghai 59
Mumbai 50
Boston 47
Norwalk 44
Florence 41
Bern 35
Boardman 35
Kent 31
Helsinki 30
Rome 29
Munich 28
Izmir 27
Jakarta 25
Milan 23
Toronto 20
Andover 17
Los Angeles 14
Hillsboro 13
Brussels 12
New York 12
Dearborn 10
London 10
Guangzhou 9
Dong Ket 8
Phoenix 8
Prescot 8
Yubileyny 8
Buenos Aires 6
Falkenstein 6
Laurel 6
Nanjing 6
Padova 6
Palermo 6
Arezzo 5
Bologna 5
Falls Church 5
Seoul 5
Tappahannock 5
Verona 5
Bremen 4
Düsseldorf 4
Frankfurt am Main 4
Hanover 4
Naples 4
Ottawa 4
Pistoia 4
Redwood City 4
Saint Petersburg 4
Washington 4
Wickford 4
Acquaviva Picena 3
Agrigento 3
Arona 3
Cagliari 3
Chennai 3
El Paso 3
Ft. Washington 3
Fuzhou 3
Hefei 3
Kilburn 3
Kunming 3
Lausanne 3
Magnago 3
Montelupo Fiorentino 3
Montepulciano 3
Napoli 3
Redmond 3
Reggio Emilia 3
San Mateo 3
Wuhan 3
Adelaide 2
Amsterdam 2
Arnsberg 2
Bani Suwayf 2
Barcelona 2
Totale 9.804
Salva come PNG Salva come JPEG
Nome #
Lesioni cutanee «specifiche» in corso di leucemia linfatica cronica. 480
CD30+ cutaneous T-cell lymphoma associated with sarcoidosis 276
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells. 269
Altered redox status in the blood of psoriatic patients: involvement of NADPH oxidase and role of anti-TNF-α therapy 267
SIRT1 regulates MAPK pathways in vitiligo skin: insight into the molecular pathways of cell survival 253
The involvement of Smac/DIABLO, p53, NF-kB and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: protective effects of curcumin and capsaicin 253
Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment 233
Ultrastructural and functional alterations of mitochondria in perilesional vitiligo skin. 220
Efalizumab in the treatment of psoriasis: when comorbidity is an issue. 182
New and experimental treatments of vitiligo and other hypomelanoses. 172
Prurigo nodularis and lichen simplex chronicus. 171
The importance of genetical link in immuno-mediated dermatoses: psoriasis and vitiligo. 166
Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. 159
Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines 150
A rational approach to the treatment of vitiligo and other hypomelanoses. 145
Retrospective analysis of systemic treatments for psoriasis patients attending a Psocare center in Florence. Relevance of biological drugs use and comorbidities. 138
Fibroblasts to keratinocytes redox signaling: The possible role of ROS in psoriatic plaque formation 136
Vogt-Koyanagi-Harada disease and vitiligo: where does the illness begin? 127
Circulating dendritic cell subsets in psoriatic patients before and after biologic therapy 126
Efalizumab-induced severe thrombocytopenia can be resolved. 124
Psoriasis and body mass index. 123
Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa 122
Treatment of Psoriasis with Efalizumab in Patients with Hepatitis C Viral Infection: Report of Five Cases. 121
Therapeutical approaches in melasma. 120
Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report. 118
Unusual presentation of tuberculosis in an infliximab-treated patient--which is the correct TB screening before starting a biologic? 118
In-vivo imaging of psoriatic lesions with polarization multispectral dermoscopy and multiphoton microscopy 118
Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: An uncommon adverse effect? 117
Mast cells do not play a role in vitiligo 115
Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience 115
Interleukin 22 early affects keratinocyte differentiation, but not proliferation, in a three-dimensional model of normal human skin. 109
Protease-activated receptor-2 downregulation is associated to vitiligo lesions 107
Morphologic and antigenic features of dendritic cells in immune-mediated dermatoses: A hypothesis of differentiation 104
Quantity, distribution and immunophenotypical modification of dendritic cells upon biological treatments in psoriasis. 103
Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry 103
Evidence for oxidative stress in the plasma of psoriatic patients: Source of ROS and results of treatments with biologics 101
Lichen planus triggered by CT-P13 and recurrence during secukinumab treatment 100
Sequential effects of photodynamic treatment of basal cell carcinoma 99
Scabies: should we always perform dermatoscopy? 97
The concept of psoriatic disease: can cutaneous psoriasis any longer be separated by the systemic comorbidities? 97
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry 94
Tuscan consensus on the diagnosis, treatment and follow-up of moderate-to-severe psoriasis 92
Induction of CD83+ CD14+ non-dendritic antigen-presenting cells by exposure of monocytes to IFN-alpha1 90
Mental health consequences of the covid-19 pandemic long-term exposure in italian dermatologists 90
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 90
NADPH Oxidase 4 as a Source of Oxidative Stress in Fibroblasts From Patients Affected by Psoriasis 89
Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus 89
The role of the dermatologist in Raynaud's Phenomenon: a clinical challenge 88
Hidradenitis suppurativa and adalimumab in the COVID-19 era 88
A mesenchyme-derived substrate is necessary for keratinocytes differentiation but not proliferation (Abs. 148). 87
Vitiligo masks malignant acanthosis nigricans in a woman with ovarian cancer 86
Source of oxidative stress in fibroblasts from patients affected by psoriasis 85
Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study 85
Reduction in psoriasis related pruritus during biologic therapy* 84
Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa 83
Clinical evaluation of topical tacalcitol efficacy in extending the remission period between nb-UVB phototherapy cycles in psoriatic patients. 82
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 82
Clinical experience with the etanercept biosimilar SB4 in psoriatic patients 82
Safety and efficacy of HCV eradication during etanercept treatment for severe psoriasis 81
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 81
Smooth-muscle actin, desmin and prolyl 4-hydroxylase in fibroblasts grown from hypertrophic scars and keloids (Abs. 99). 80
Possible reconsideration of the Nail Psoriasis Severity Index (NAPSI) score 79
Epidemiology of Psoriasis and Psoriatic Arthritis in Italy—a Systematic Review 79
Curcumin and capsaicin prevent mitochondrial damage and apoptosis in keratinocytes from perilesional vitiligo skin 76
Effects of cyclosporin-A on the morphology of human Langerhans cells in cultured epidermal sheets Abs. 7). 76
Clinical experience with infliximab biosimilar in psoriasis 76
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study 76
Clinical characteristics of psoriasis in inflammatory bowel disease patients 75
Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study 75
Photodynamic therapy and apoptosis in cutaneous basal cell carcinoma (Abs 002). 74
Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: a combined approach by QuantiFERON-TB Gold and tuberculin skin tests. 74
Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis 74
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice 74
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions 74
High frequency ultrasound can detect improvement of lesions in juvenile localized scleroderma 74
Cutaneous hyperpigmentation induced by apremilast 74
Ultrasound detects occult entheseal involvement in early psoriatic arthritis independently of clinical features and psoriasis severity. 73
Comment on “Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?” 73
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders 73
Effectiveness and safety of anti-interleukin-17 therapies in elderly patients with psoriasis 73
Human stem cell factor does not affect the morphology and expression of functionally relevant molecules of Langerhans cells in vitro (Abs. 571). 72
Effects of GM-CSF and TNF-alpha on the Langerhans cells of human epidermal sheets (Abs. 827). 72
Ultrasonographic wrist and hand abnormalities in early psoriatic arthritis patients: Correlation with clinical, dermatological, serological and genetic indices 72
First case of secukinumab successful therapy in a very elderly psoriatic patient 72
Hidradenitis suppurativa and associated diseases 72
Alpha-smooth muscle actin axpression by fibroblasts is not a marker of hypertrophic scars in vitro (Abs. 774). 71
Intermediate filament proteins of keratinocytes under different culture conditions (Abs. 244). 71
A pediatric case of sclerodermatous graft-versus-host disease responsive to ultraviolet A1 phototherapy 71
Intellectual Disability and Hidradenitis Suppurativa 71
Factors influencing number and differentiation of Langerhans cells within epidermis (Abs P9). 70
Granulocyte macrophage-colony stimulating factor augments the functional activity of LC in vitro. 70
Tumor necrosis factor-alpha and interleukin-17 differently affects Langerhans cell distribution and activation in an innovative three-dimensional model of normal human skin 70
Oxidative stress in the pathogenesis of vitiligo 69
Ultrastructural mitochondrial alterations and oxidative damage in keratinocytes from perilesional vitiligo skin 68
Involvement of PAR-2 in vitiligo 67
COVID-19 and psoriasis: Should we fear for patients treated with biologics? 67
Epidermal barrier reaction to an in vitro psoriatic microenvironment 67
Atypical mycobacteria 67
Insights into the pathogenesis of HS and therapeutical approaches 66
SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis 66
Totale 10.875
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.935
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.935
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020647 0 0 0 0 0 0 155 170 121 84 92 25
2020/2021811 69 70 55 65 34 109 35 69 77 101 58 69
2021/20221.249 33 60 51 29 6 102 184 87 64 41 326 266
2022/20232.763 292 681 127 180 157 493 325 99 242 16 71 80
2023/2024924 38 81 186 43 36 65 49 215 18 76 75 42
2024/20255.706 323 897 536 982 2.135 829 4 0 0 0 0 0
Totale 14.038